0001656472-21-000048 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2021	May 06, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	111 Peter St. Suite 300
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M5V 2H1
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		371,656,590
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001656472
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2021

Dec. 31, 2020

Current assets

Cash and cash equivalents

$ 1,024,450

$ 1,078,023

Short-term investments

214,925

211,766

Accounts receivable, net

^[1]

6,997

8,928

Other receivables

3,796

10,033

Current portion of loans receivable, net

^[2]

6,717

7,083

Prepaids and other current assets

15,053

11,161

Inventory, net

46,437

44,002

Held-for-sale assets

1,969

1,176

Total current assets

1,320,344

1,372,172

Advances to joint ventures

487

467

Investments in equity accounted investees, net

19,221

19,235

Loans receivable, net

90,953

87,191

Property, plant and equipment, net

192,123

187,599

Right-of-use assets

8,538

9,776

Intangible assets, net

70,085

69,720

Goodwill

179,531

179,522

Total assets

1,881,282

1,925,682

Current liabilities

Accounts payable and other liabilities

29,213

42,102

Current portion of lease obligation

1,130

1,322

Derivative liabilities

272,300

163,410

Total current liabilities

302,643

206,834

Due to non-controlling interests

2,129

2,188

Lease obligation

8,231

8,492

Total liabilities

313,003

217,514

Commitments and contingencies

^[3]

Shareholders’ equity

Share capital

^[4],[5]

584,912

569,260

Additional paid-in capital

32,090

34,596

Retained earnings

895,503

1,064,509

Accumulated other comprehensive income

58,144

42,999

Total equity attributable to shareholders of Cronos Group

1,570,649

1,711,364

Non-controlling interests

(2,370)

(3,196)

Total shareholders’ equity

1,568,279

1,708,168

Total liabilities and shareholders’ equity

$ 1,881,282

$ 1,925,682

[1]	Net of current expected credit loss allowance on accounts receivable of $66 and $74 as of March 31, 2021 and December 31, 2020, respectively.
[2]	Net of current expected credit loss allowance on loans receivable of $3,020 and $2,439 as of March 31, 2021 and December 31, 2020, respectively.
[3]	Refer to Note 9. Commitments and Contingencies in the notes to condensed consolidated financial statements.
[4]	Authorized for issuance as of March 31, 2021: unlimited and December 31, 2020: unlimited.
[5]	Shares issued as of March 31, 2021: 371,656,590 and December 31, 2020: 360,253,332

Condensed Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Current expected credit loss allowance on accounts receivable	$ 66	$ 74
Current expected credit loss allowance on loans receivable	$ 3,020	$ 2,439
Common stock, shares issued (in shares)	371,656,590	360,253,332

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) - USD ($)

3 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Income Statement [Abstract]

Net revenue, before excise taxes

$ 14,654,000

$ 9,344,000

Excise taxes

(2,043,000)

(912,000)

Net revenue

12,611,000

8,432,000

Cost of sales

15,574,000

6,946,000

Inventory write-down

7,962,000

Gross profit (loss)

(2,963,000)

(6,476,000)

Operating expenses

Sales and marketing

10,254,000

7,112,000

Research and development (“R&D”)

5,102,000

4,590,000

General and administrative

21,906,000

23,759,000

Share-based payments

2,499,000

2,436,000

Depreciation and amortization

735,000

687,000

Total operating expenses

40,496,000

38,584,000

Operating loss

(43,459,000)

(45,060,000)

Other income (loss)

Interest income, net

2,329,000

7,751,000

Gain (loss) on revaluation of derivative liabilities

(116,874,000)

113,368,000

Impairment loss on property, plant and equipment and right-of-use assets

(1,741,000)

Other loss

(1,859,000)

(378,000)

Total other income (loss)

(118,145,000)

120,741,000

Income (loss) from continuing operations

(161,604,000)

75,681,000

Loss from discontinued operations

(21,000)

Net income (loss)

(161,625,000)

75,681,000

Net income (loss) attributable to:

Cronos Group

(161,312,000)

76,040,000

Non-controlling interests

(313,000)

(359,000)

Net income (loss)

(161,625,000)

75,681,000

Other comprehensive income (loss)

Foreign exchange gain (loss) on translation

16,284,000

(113,692,000)

Total other comprehensive income (loss)

16,284,000

(113,692,000)

Comprehensive loss

(145,341,000)

(38,011,000)

Comprehensive income (loss) attributable to:

Cronos Group

(146,167,000)

(37,675,000)

Non-controlling interests

826,000

(336,000)

Comprehensive income (loss)

$ (145,341,000)

$ (38,011,000)

Net income (loss) per share

Basic - continuing operations (in dollars per share)

^[1]

$ (0.44)

$ 0.22

Diluted - continuing operations (in dollars per share)

^[1],[2]

$ (0.44)

$ 0.20

Weighted average number of outstanding shares

Basic (in shares)

363,012,740

348,817,472

Diluted (in shares)

363,012,740

374,330,168

[1]	For the three months ended March 31, 2021 and 2020, the Company reported a basic and diluted loss from discontinued operations of $0.00 per share and $0.00 per share and $0.00 per share and $0.00 per share, respectively. See Note 7. Earnings (Loss) per Share.
[2]	In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. See Note 7. Earnings (Loss) per Share.

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Basic loss per share - discontinued operations (in dollars per share)	$ 0.00	$ 0.00
Diluted loss per share - discontinued operations (in dollars per share)	$ 0.00	$ 0.00

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2019		348,817,472
Beginning balance at Dec. 31, 2019	$ 1,749,030	$ 561,165	$ 23,234	$ 1,137,646	$ 27,838	$ (853)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of options	1,730		1,730
Vesting of restricted share units	706		706
Vesting of common shares issued in connection with the use of certain publicity rights in brand development	1,813	$ 2,000	(187)
Net income (loss)	75,681			76,040		(359)
Foreign exchange gain (loss) on translation	(113,692)				(113,715)	23
Ending balance (in shares) at Mar. 31, 2020		348,817,472
Ending balance at Mar. 31, 2020	1,715,268	$ 563,165	25,483	1,213,686	(85,877)	(1,189)
Beginning balance (in shares) at Dec. 31, 2020		360,253,332
Beginning balance at Dec. 31, 2020	1,708,168	$ 569,260	34,596	1,064,509	42,999	(3,196)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Warrants exercised (in shares)		7,832,859
Warrants exercised	0	$ 1,161	(1,161)
Vesting of options	$ 2,064		2,064
Options exercised (in shares)	5,230,550	3,570,399
Options exercised	$ 10	$ 3,213	(3,203)
Vesting of restricted share units	435		435
Withholding taxes paid on share-based awards	(8,673)		(979)	(7,694)
Vesting of common shares issued in connection with the use of certain publicity rights in brand development	338		338
Top-up rights exercised	11,278	$ 11,278
Net income (loss)	(161,625)			(161,312)		(313)
Foreign exchange gain (loss) on translation	16,284				15,145	1,139
Ending balance (in shares) at Mar. 31, 2021		371,656,590
Ending balance at Mar. 31, 2021	$ 1,568,279	$ 584,912	$ 32,090	$ 895,503	$ 58,144	$ (2,370)

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating activities
Net income (loss)	$ (161,625,000)	$ 75,681,000
Items not affecting cash:
Inventory write-down	0	7,962,000
Share-based payments	2,499,000	2,436,000
Depreciation and amortization	1,880,000	1,162,000
Gain (loss) on revaluation of derivative liabilities	116,874,000	(113,368,000)
Impairment loss on property, plant and equipment and right-of-use assets	1,741,000	0
Expected credit losses on financial assets and non-cash charges to inventory	681,000	2,068,000
Other non-cash operating activities, net	1,749,000	643,000
Changes in non-cash working capital:
Accounts receivable, net	1,931,000	472,000
Other receivables	5,687,000	(1,235,000)
Prepaids and other current assets	(3,737,000)	(2,439,000)
Inventory, net	(1,007,000)	(14,319,000)
Accounts payable and other liabilities	(12,675,000)	2,039,000
Cash flows used in operating activities	(46,002,000)	(38,898,000)
Investing activities
Proceeds from (purchase of) short-term investments, net	0	80,333,000
Purchase of property, plant and equipment	(6,680,000)	(6,411,000)
Purchase of intangible assets	(392,000)	(1,105,000)
Advances on loans receivable	(2,645,000)	(14,512,000)
Other non-cash investing activities, net	0	781,000
Cash flows provided by (used in) investing activities	(9,717,000)	59,086,000
Financing activities
Repayment of lease obligations	(613,000)	(448,000)
Withholding taxes paid on share-based awards	(8,673,000)	0
Other non-cash investing activities, net	10,000	0
Cash flows provided by (used in) financing activities	(9,276,000)	(448,000)
Effect of foreign currency translation on cash and cash equivalents	11,422,000	(91,037,000)
Net change in cash and cash equivalents	(53,573,000)	(71,297,000)
Cash and cash equivalents, beginning of period	1,078,023,000	1,199,693,000
Cash and cash equivalents, end of period	1,024,450,000	1,128,396,000
Supplemental cash flow information
Interest paid	0	7,000
Interest received	1,157,000	7,758,000
Income taxes paid	$ 624,000	$ 0

Background, Basis of Presentation and Accounting Policies	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background, Basis of Presentation and Accounting Policies	Background, Basis of Presentation and Accounting Policies (a)Background Cronos Group Inc. (“Cronos Group” or the “Company”) is incorporated in the Province of British Columbia and under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter Street, Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.” Cronos Group is an innovative global cannabinoid company, with international production and distribution across five continents. The Company is committed to building disruptive intellectual property by advancing cannabis research, technology and product development and is seeking to build an iconic brand portfolio. Cronos Group’s brand portfolio includes PEACE NATURALS™, a global wellness platform; two adult-use brands, COVE™ and Spinach™; and three U.S. hemp-derived consumer products brands, Lord Jones™, Happy Dance™ and PEACE+™. Cronos Group has established strategic joint ventures in Canada, Israel, and Colombia. Cronos Israel (as defined herein) is consolidated for financial reporting purposes. The Company also holds approximately 31% of the issued capital of Cronos Australia Limited (“Cronos Australia”) and accounts for its investment in Cronos Australia under the equity method of accounting. For additional discussion regarding the joint ventures and strategic investment, see Note 3. Investments in Equity Accounted Investees, net. (b)Out-of-period adjustments The Company identified an error in the accounting related to the withholding taxes on the net exercise of stock options, which resulted in an understatement of accounts payable and other liabilities of $966 and overstatements of other receivables, retained earnings and common stock of $3,202, $3,838 and $330, respectively, as of December 31, 2020. The error was deemed immaterial, and thus the Company has recorded an out-of-period adjustment to the condensed consolidated balance sheet and the condensed consolidated statement of changes in equity as of March 31, 2021 to correct the error. This error had no impact to the condensed consolidated statement of net income (loss) and comprehensive income (loss). The impact of the out-of-period adjustments are included within the changes in non-cash working capital and withholding taxes paid on share-based awards lines in the Company’s condensed consolidated statements of cash flows. (c)Basis of presentation The interim condensed consolidated financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Annual Financial Statements”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated financial statements. These reclassifications had no effect on the reported results of operations and ending shareholder’s equity. (d)Adoption of new accounting pronouncements On January 1, 2021, the Company adopted ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU No. 2020-01”). ASU No. 2020-01 clarifies the interaction of accounting for the transition into and out of the equity method as well as measuring certain purchased options and forwards contracts to acquire investments. The adoption of ASU No. 2020-01 did not have an impact on the Company’s interim condensed consolidated financial statements. On January 1, 2021, the Company adopted ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). ASU No. 2019-12 eliminates certain exceptions and simplifies the application of U.S. GAAP-related changes in enacted tax laws or rates and employee stock option plans. The adoption of ASU No. 2019-12 did not have an impact on the Company’s interim condensed consolidated financial statements. (e)New accounting pronouncements not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging –Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU No. 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU No. 2020-06 will have on its interim condensed consolidated financial statements.

Inventory, net

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Inventory, net

Inventory, net is comprised of the following items:


	As of March 31, 2021		As of December 31, 2020
Raw materials, net	$	11,182	$	11,489
Work-in-progress – dry cannabis, net	21,590		20,520
Work-in-progress – cannabis extracts, net	5,036		5,758
Finished goods – dry cannabis, net	5,677		4,894
Finished goods – cannabis extracts, net	2,141		1,011
Supplies and consumables	811		330
Total	$	46,437	$	44,002

Inventory is written down for any obsolescence such as slow-moving or non-marketable products, or when the net realizable value of inventory is less than the carrying value. For the three months ended March 31, 2021 and 2020, the Company recorded write-downs related to inventory of $nil and $7,962, respectively.

Investments in Equity Accounted Investees, net

3 Months Ended

Mar. 31, 2021

Equity Method Investments and Joint Ventures [Abstract]

Investments in Equity Accounted Investees, net

The Company holds variable interests in Cronos Growing Company Inc. (“Cronos GrowCo”), Natuera S.à.r.l (“Natuera”), MedMen Canada Inc. (“MedMen Canada”) and Cannasoul Lab Services Ltd. (“CLS”).

Cronos GrowCo is a joint venture incorporated under the Canada Business Corporations Act (“CBCA”) on June 14, 2018 with the objective of cultivating and commercializing cannabis and cannabis products. Cronos Group holds variable interests in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt. Cronos GrowCo’s economic performance is driven by the quantity and strains of cannabis grown. The joint venture partners mutually determine the quantity and strains of cannabis grown.

MedMen Canada is a joint venture incorporated under the CBCA on March 13, 2018, with the objective of the retail sale and marketing of cannabis products in Canada. MedMen Canada holds the exclusive license to the MedMen brand in Canada for a minimum term of 20 years. Cronos holds variable interests in MedMen Canada through its ownership of 50% of MedMen Canada’s common shares and other subordinated debt. MedMen Canada’s economic performance is driven by the quantity and strains of cannabis sold. Subject to applicable law, the joint venture partners mutually determine the quantity and strains of cannabis to be sold in MedMen Canada’s retail stores, if and when stores are opened.

Natuera is a joint venture registered in Luxembourg with the objective of cultivating and commercializing hemp and cannabis products. Cronos holds variable interests in Natuera through its ownership of 50% of Natuera’s common shares and other debt. Natuera’s economic performance is driven by the quantity and strains of cannabis grown, which is mutually determined by the joint venture partners.

The Company’s investments in Cronos GrowCo, Natuera and MedMen Canada are exposed to economic variability from each entity’s performance; however, the Company does not consolidate the entities as it does not have the power to direct the activities that most significantly impact each entity’s economic performance. Thus, Cronos Group is not considered the primary beneficiary of each entity. These investments are accounted for as equity method investments classified as “Investments in equity accounted investees, net” in the consolidated balance sheets.

CLS is a wholly owned subsidiary of Cannasoul Analytics Ltd., incorporated with the purpose of establishing a commercial cannabis analytical testing laboratory located on the premises of Cronos Israel (the “Cannasoul Collaboration”). Cronos Israel agreed to advance up to ILS 8,297 ($2,483) by a non-recourse loan to CLS over a period of two years from April 1, 2020 for the capital and operating expenditures of the laboratory. The loan bears interest at 3.5% annually. Cronos Israel will receive 70% of the profits of the laboratory until such time as it has recovered 150% of the amounts advanced to CLS, after which time it will receive 50% of the laboratory profits. As a result, the Company is exposed to economic variability from CLS’s performance. The Company does not consolidate CLS as it does not have the power to direct the activities that most significantly impact the entity’s economic performance; thus, the Company is not considered the primary beneficiary of the entity. The carrying amount of the non-recourse loan is recorded under loans receivable and the full loan amount, ILS 8,297, represents the Company’s maximum potential exposure to losses through the Cannasoul Collaboration. See Note 4. Loans Receivable, net for further information regarding loans receivable.

A reconciliation of the carrying amount of the investments in associates and joint ventures is as follows:


	Ownership interest	As of March 31, 2021		As of December 31, 2020
Cronos Australia	31%	$	—	$	—
Cronos GrowCo	50%	$	19,221	$	19,235
Natuera	50%	—		—
		$	19,221	$	19,235

The Company’s share of net earnings (losses) from equity investments accounted for under the equity method of accounting:


	For the three months ended March 31,
		2021		2020



Cronos GrowCo		$	(299)	$	(311)

Natuera(i)		(1,344)		(861)

		$	(1,643)	$	(1,172)

(i) The Company’s share of accumulated net losses in excess of its equity investment in Natuera has been applied as a loss allowance on the loan receivable. See Note 4. Loans Receivable, net.

The Company determined that the maximum exposure of loss on investments in non-consolidated investments is limited to the Company’s initial investment, advances and/or loans for each variable interest entity. The following is a summary of the maximum exposure to loss as of March 31, 2021 and December 31, 2020:


	Ownership interest	As of March 31, 2021			As of December 31, 2020
Cronos Australia	31%		$	1,553	$	1,530
Cronos GrowCo	50%		21,433		21,125
MedMen Canada	50%		487		467
Natuera	50%		8,160		8,154
Total			$	31,633	$	31,276

Loans Receivable, net

3 Months Ended

Mar. 31, 2021

Receivables [Abstract]

Loans Receivable, net


	As of March 31, 2021		As of December 31, 2020
Natuera Series A loan(i)	$	2,013	$	3,518
GrowCo Facility(ii)	796		3,137
Add: Accrued interest	3,908		428
Total current portion of loans receivable	6,717		7,083
GrowCo Facility(ii)	76,043		69,939
Mucci promissory note(iii)	13,654		13,324
Cannasoul collaboration loan(iv)	1,215		1,261
Add: Accrued interest	41		2,667
Total long-term portion of loans receivable	90,953		87,191
Total loans receivable, net	$	97,670	$	94,274

(i)As of March 31, 2021 and December 31, 2020, a current expected credit loss allowance of $1,151 and $685, respectively, was recorded against the master loan agreement entered into with Natuera on September 27, 2019 (the “Series A loan”). As of March 31, 2021 and December 31, 2020, a loss allowance of $4,582 and $3,024, respectively, was recorded against the Series A Loan related to the Company’s share of net loss from Natuera in excess of the carrying value of the equity method investment. Refer to Note 3 and Note 14.

(ii)As of March 31, 2021 and December 31, 2020, Cronos GrowCo had drawn C$98,500 ($78,405) and C$95,150 ($74,626), respectively, from a credit agreement it entered into with the Company in August 2019 (the “GrowCo Facility”). As of March 31, 2021 and December 31, 2020, a current expected credit loss allowance of $1,569 and $1,470, respectively, was recorded against the GrowCo Facility.

(iii)As of March 31, 2021 and December 31, 2020, a current expected credit loss allowance of $274 and $259, respectively, was recorded against the Mucci promissory note.

(iv)As of March 31, 2021 and December 31, 2020 CLS has received ILS 4,149 (approximately $1,241) from a non-recourse loan. As of March 31, 2021 and December 31, 2020 a current expected credit loss allowance of $26 and $25, respectively, was recorded against the Cannasoul collaboration loan.

Derivative Liabilities

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liabilities

On March 8, 2019, the Company closed the previously announced investment in the Company (the “Altria Investment”) by Altria Group, Inc. (“Altria”), pursuant to a subscription agreement dated December 7, 2018. As of the closing date of the Altria Investment, the Altria Investment consisted of 149,831,154 common shares of the Company and one warrant of the Company (the “Altria Warrant”), all of which were issued to a wholly owned subsidiary of Altria. As of the closing date of the Altria Investment, Altria beneficially held an approximately 45% ownership interest in the Company (calculated on a non-diluted basis). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 55% (calculated on a non-diluted basis). Pursuant to the investor rights agreement between the Company and Altria, entered into in connection with the closing of the Altria Investment (the “Investor Rights Agreement”), the Company granted Altria certain rights, among others, summarized in this note.

The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable.

a.The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to an additional 10% of the common shares of Cronos (approximately 82.6 million common shares at March 31, 2021) at a per share exercise price of C$19.00, which expires on March 8, 2023.

b.The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the R&D partnership with Ginkgo Bioworks Inc. (“Ginkgo”) (the “Ginkgo Strategic Partnership”)), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance. The price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Strategic Partnership will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%.

c.In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”).

The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX for the ten full days preceding such exercise by Altria, provided that the price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that were outstanding as of March 8, 2019 will be C$16.25 per common share without any set off, counterclaim, deduction, or withholding. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. The Altria Warrant, Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities.

A reconciliation of the carrying amounts of the derivative liability for the three months ended March 31, 2021 and 2020:


	As of January 1, 2021		Revaluation (gain)/loss		Exercise of rights		Foreign exchange effect		As of March 31, 2021
(a) Altria Warrant	$	138,858	$	92,964	$	—	$	2,834	$	234,656
(b) Pre-emptive Rights	12,095		7,833		—		245		20,173
(c) Top-up Rights	12,457		16,077		(11,278)		215		17,471
	$	163,410	$	116,874	$	(11,278)	$	3,294	$	272,300


	As of January 1, 2020		Revaluation (gain)/loss		Exercise of rights		Foreign exchange effect		As of March 31, 2020
(a) Altria Warrant	$	234,428	$	(88,104)	$	—	$	(13,958)	$	132,366
(b) Pre-emptive Rights	12,787		1,315		—		(1,032)		13,070
(c) Top-up Rights	49,945		(26,579)		—		(2,626)		20,740
	$	297,160	$	(113,368)	$	—	$	(17,616)	$	166,176

Fluctuations in the Company’s share price are a primary driver for the changes in the derivative valuations during each reporting period. As the share price decreases for each of the related derivative instruments, the liability of the instrument generally decreases. Share price is one of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments. During the three months ended March 31, 2021, the Company’s share price increased from December 31, 2020 resulting in a loss on revaluation of $116,874. During the three months ended March 31, 2020, the Company’s share price decreased from December 31, 2019 resulting in a gain on revaluation of $113,368.

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model as of March 31, 2021 and December 31, 2020 applying the following inputs:


	As of March 31, 2021			As of December 31, 2020
	Altria Warrant	Pre-emptive Rights	Top-up Rights	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price at valuation date (i)	$11.88	$11.88	$11.88	$8.84	$8.84	$8.84
Subscription price (i)	$19.00	$16.25	$16.25	$19.00	$16.25	$16.25
Weighted average risk-free interest rate (ii)	0.22%	0.17%	0.14%	0.21%	0.17%	0.13%
Weighted average expected life (iii)	1.93	1.25	0.72	2.18	1.50	0.98
Expected annualized volatility (iv)	82%	82%	82%	81%	81%	81%
Expected dividend yield	—%	—%	—%	—%	—%	—%

(i)Per share in C$.

(ii)The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of March 31, 2021 and December 31, 2020, the risk-free interest rate uses a range of approximately 0.09% to 0.86% and 0.10% to 0.39%, respectively, for the Pre-emptive Rights and Top-up Rights.

(iii)The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of March 31, 2021 and December 31, 2020, the expected life uses a range of approximately 0.25 year to 4.50 years and 0.50 year to 5.00 years, respectively.

(iv)Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company as of March 31, 2021. As of December 31, 2020, volatility was based on the blended historical volatility levels of the Company and peer companies.

The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying value of the derivative liability, there would also be an equal but opposite impact on net income (loss) as of March 31, 2021.


	Increase as of March 31, 2021
	Altria Warrant		Pre-emptive Rights		Top-up Rights
Share price	$	42,479	$	4,133	$	4,376
Weighted average expected life	18,051		3,039		683
Expected annualized volatility	35,099		2,865		2,785

These inputs are classified in Level 3 on the fair value hierarchy and are subject to volatility and several factors outside of the Company’s control, which could significantly affect the fair value of these derivative liabilities in future periods.

Share-based Payments

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-based Payments

(a)Share-based award plans

The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans.

The following table summarizes the total stock-based compensation expense associated with the Company’s stock options and RSUs for the three months ended March 31, 2021 and 2020:


	For the three months ended March 31,
	2021		2020
Vesting of stock options	$	2,064	$	1,730
Vesting of RSUs	435		706
Total share-based payments	$	2,499	$	2,436

(b)Stock options

Vesting conditions for grants of options are determined by the Compensation Committee of the Company’s Board of Directors. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three to five years with a maximum term of ten years. The typical vesting for stock option grants made under the Prior Option Plans is quarterly vesting over three to five years with a maximum term of seven years. The Prior Option Plans did not and the 2020 Omnibus Plan does not authorize grants of options with an exercise price below fair market value.

The following is a summary of the changes during the three months ended March 31, 2021 and 2020:


	Weighted average exercise price (C$) (i)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2021	$	5.40	13,755,148	2.30

Exercise of options	2.13		(5,230,550)
Cancellation, forfeiture and expiry of options	14.71		(25,771)
Balance as of March 31, 2021	$	7.38	8,498,827	2.82
Exercisable as of March 31, 2021	$	5.75	4,896,820	1.46

(i)The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.


	Weighted average exercise price (C$)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2020	$	4.84	14,149,502	2.56


Cancellation, forfeiture and expiry of options	17.17		(42,889)
Balance as of March 31, 2020	$	4.80	14,106,613	2.06
Exercisable as of March 31, 2020	$	3.11	9,783,544	1.66

The following table summarizes stock options outstanding for the 2020 Omnibus Plan, the 2018 Stock Option Plan, and the 2015 Stock Option Plan:


	Stock options outstanding as of
	March 31, 2021	December 31, 2020
2020 Omnibus Plan	2,000,000	2,000,000
2018 Stock Option Plan	1,591,944	1,627,715
2015 Stock Option Plan	4,906,883	10,127,433
Total stock options outstanding	8,498,827	13,755,148

(c)Restricted share units

The following is a summary of the changes in RSUs for the three months ended March 31, 2021 and 2020:


	Number of RSUs (i)	Weighted average grant date fair value (C$) (ii)
Balance as of January 1, 2021	948,357	$	7.66
Granted(i)	265,904	13.27


Balance as of March 31, 2021	1,214,261	$	8.89

(i)RSUs issued in the period vest annually in equal installments over a three-year period following the grant date, subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.

(ii)The weighted average exercise price reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.


	Number of RSUs	Weighted average grant date fair value (C$)
Balance as of January 1, 2020 and March 31, 2020	732,972	$	15.34

All RSUs outstanding as of March 31, 2021 and December 31, 2020 were granted under the 2020 Omnibus Plan.

(d)Deferred share units

The following is a summary of the changes in DSUs during the three months ended March 31, 2021 and 2020:


	Number of DSUs	Financial liability
Balance as of January 1, 2021	83,293	$	577


Loss (gain) on revaluation	—	211
Balance as of March 31, 2021	83,293	$	788


	Number of DSUs	Financial liability
Balance as of January 1, 2020	33,937	$	255


Loss (gain) on revaluation	—	(50)
Balance as of March 31, 2020	33,937	$	205

All DSUs outstanding as of March 31, 2021 and December 31, 2020 were granted under the DSU Plan.

(e)Warrants

The following is a summary of the changes in warrants during the three months ended March 31, 2021 and 2020:


	Weighted average exercise price (C$)		Number of warrants
Balance as of January 1, 2021	$	0.25	7,987,349
Exercise of warrants	0.25		(7,977,349)

Balance as of March 31, 2021(i)	$	0.25	10,000

(i)The outstanding warrants were granted in the second quarter of 2016 and expire on May 27, 2021.


	Weighted average exercise price (C$)		Number of warrants
Balance as of January 1, 2020 and March 31, 2020	$	0.26	18,066,662

See Note 5. Derivative Liabilities for further description on the Altria Warrant.

Earnings (Loss) Per Share

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

Earnings (Loss) per Share

Basic and diluted earnings (loss) per share from continuing operations are calculated using the following numerators and denominators:


	For the three months ended March 31,
	2021		2020
Basic earnings per share computation
Net income (loss) attributable to common shareholders of Cronos Group	$	(161,312)	$	76,040
Weighted average number of common shares outstanding	363,012,740		348,817,472
Basic earnings per share(i)	$	(0.44)	$	0.22
Diluted earnings per share computation
Net income (loss) used in the computation of basic earnings per share	$	(161,312)	$	76,040
Adjustment for gain (loss) on revaluation of derivative liabilities	—		—
Net income (loss) used in the computation of diluted income per share	$	(161,312)	$	76,040

Weighted average number of common shares outstanding used in the computation of basic earnings per share	363,012,740		348,817,472
Dilutive effect of warrants	—		17,550,444
Dilutive effect of stock options	—		7,962,252



Weighted average number of common shares for computation of diluted income (loss) per share	363,012,740		374,330,168
Diluted earnings per share(i)	$	(0.44)	$	0.20

(i)Basic and dilutive earnings per share from discontinued operations were $0.00 and $0.00 for the three months ended March 31, 2021 and 2020, respectively.

(ii)In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.

The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because conditions for contingently issuable shares were not satisfied at the end of the reporting periods.


	Three months ended March 31,
	2021	2020
Ginkgo equity milestones	14,674,904	14,674,904
Pre-emptive Rights	11,285,001	12,006,740
Top-up Rights – fixed price	11,113,451	25,111,456
Top-up Rights – market price	2,623,082	1,941,349
Altria Warrant	82,590,353	77,514,993
Stock options	8,522,086	2,240,456
Warrants	5,563,176	—
Restricted share units	572,970	732,972
Total anti-dilutive securities	136,945,023	134,222,870

Segment Information

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Segment Information

Segment reporting is prepared on the same basis that the Company’s chief operating decision makers (the “CODMs”) manage the business, make operating decisions and assess the Company’s performance. The Company determined that it has the following two reportable segments: United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODMs to assess the performance of the segment and make decisions regarding the allocation of resources. The CODMs review adjusted earnings (loss) before interest, tax, depreciation and amortization (“Adjusted EBITDA”) as the measure of segment profit or loss to evaluate performance of and allocate resources for its reportable segments. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of on-going business performance.

Segment data was as follows for the three months ended March 31, 2021 and 2020:


	Three months ended March 31, 2021
	United States		Rest of World		Corporate expenses		Total
Net revenue
Cannabis flower	$	—	$	9,434	$	—	$	9,434
Cannabis extracts	2,441		703		—		3,144
Other	—		33		—		33
Net revenue	$	2,441	$	10,170	$	—	$	12,611

Share of loss from investments in equity accounted investees	$	—	$	1,643	$	—	$	1,643

Interest income	3		2,332		—		2,335
Interest expense	—		(6)		—		(6)
Interest income, net	$	3	$	2,326	$	—	$	2,329

Depreciation and amortization	$	71	$	664	$	—	$	735
Impairment loss on property, plant and equipment and right-of-use assets	1,741		—		—		1,741
Loss from discontinued operations	—		21		—		21
Adjusted EBITDA	(9,510)		(22,184)		(5,381)		(37,075)

Total assets	252,449		394,442		1,234,391		1,881,282
Investments in equity accounted investees	—		19,221		—		19,221
Goodwill	178,416		1,115		—		179,531
Purchase of property, plant and equipment, net	80		6,600		—		6,680


	Three months ended March 31, 2020
	United States		Rest of World		Corporate expenses		Total
Net revenue
Cannabis flower	$	—	$	2,741	$	—	$	2,741
Cannabis extracts	2,176		3,400		—		5,576
Other	—		115		—		115
Net revenue	$	2,176	$	6,256	$	—	$	8,432

Share of loss from investments in equity accounted investees	$	—	$	1,172	$	—	$	1,172

Interest income	7		7,751		—		7,758
Interest expense	—		(7)		—		(7)
Interest income, net	$	7	$	7,744	$	—	$	7,751

Depreciation and amortization	33		654		—		687

Adjusted EBITDA	$	(5,782)	$	(29,010)	$	(2,263)	$	(37,055)

Adjusted EBITDA is reconciled to net income (loss) as follows for the three months ended March 31, 2021 and 2020:


(In thousands of U.S. dollars)	Three months ended March 31, 2021
	US		ROW		Corporate Expenses		Total
Net income (loss)	$	(12,092)	$	(142,147)	$	(7,386)	$	(161,625)
Adjustments
Interest income, net	(3)		(2,326)		—		(2,329)


Impairment loss on property, plant and equipment and right-of-use assets	1,741		—		—		1,741
Loss on revaluation of derivative liabilities	—		116,874		—		116,874

Other loss	—		1,859		—		1,859
Loss from discontinued operations	—		21		—		21
Share-based payments	745		1,754		—		2,499
Review costs related to restatement of 2019 interim financial statements	—		—		2,005		2,005
Adjusted EBIT	(9,609)		(23,965)		(5,381)		(38,955)
Adjustments
Depreciation and amortization	99		1,781		—		1,880
Adjusted EBITDA	$	(9,510)	$	(22,184)	$	(5,381)	$	(37,075)


(In thousands of U.S. dollars)	Three months ended March 31, 2020
	US		ROW		Corporate Expenses		Total
Net income (loss)	$	(6,516)	$	88,867	$	(6,670)	$	75,681
Adjustments
Interest income, net	(7)		(7,744)		—		(7,751)


Gain on revaluation of derivative liabilities	—		(113,368)		—		(113,368)
Other loss	—		378		—		378

Share-based payments	706		1,730		—		2,436
Review costs related to restatement of 2019 interim financial statements	—		—		4,407		4,407
Adjusted EBIT	(5,817)		(30,137)		(2,263)		(38,217)
Adjustments
Depreciation and amortization	35		1,127		—		1,162
Adjusted EBITDA	$	(5,782)	$	(29,010)	$	(2,263)	$	(37,055)

Sources of net revenue for the three months ended March 31, 2021 and 2020 were as follows:


	Three months ended March 31,
		2021		2020
Cannabis flower		$	9,434	$	2,741
Cannabis extracts		3,144		5,576
Other		33		115
Net revenue		$	12,611	$	8,432

Net revenue attributed to a geographic region based on the location of the customer were as follows:


	Three months ended March 31,
		2021		2020
Canada		$	7,582	$	6,091
Israel		2,518		—
United States		2,441		2,176
Other countries		70		165
Net revenue		$	12,611	$	8,432

Property, plant and equipment assets were physically located in the following geographic regions:


	As of March 31, 2021		As of December 31, 2020
Canada	$	167,363	$	162,163
Israel	23,480		23,143
United States	1,280		2,293

Total	$	192,123	$	187,599

The Company sells products through a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenues and greater than 10% of accounts receivable.

United States

During the three months ended March 31, 2021 and 2020, the U.S. segment had no major customers.

As of March 31, 2021 and December 31, 2020, the Company had $36 and $65, respectively, in expected credit losses that have been recognized on receivables from contracts with customers.

Rest of World

During the three months ended March 31, 2021, the Rest of World segment earned a total net revenue before excise taxes of $8,963 from four major customers, Société Québécoise du Cannabis, Novolog Group, Alberta Gaming, Liquor and Cannabis Commission and Ontario Cannabis Retail Corporation, accounting for 18%, 17%, 13% and 13%, respectively, of the Company’s total net revenue before excise taxes.

During the three months ended March 31, 2020, the Rest of World segment earned a total net revenue before excise taxes of $4,121 from 3 major customers, together accounting for 49% of the Company’s total net revenues before excise taxes.

As of March 31, 2021 and December 31, 2020, the Company had $30 and $9, respectively, in expected credit losses that have been recognized on receivables from contracts with customers.

The loss from discontinued operations from the Rest of World segment for the three months ended March 31, 2021 and 2020 was $21 and $nil, respectively.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2021
Loss Contingency [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a)Commitments There has been no material change in the information regarding commitments as disclosed in the Company’s Annual Financial Statements. (b)Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter. (i)Class action complaints relating to restatement On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its former Chief Executive Officer (now Executive Chairman) and Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal controls were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names the Company, its former Chief Executive Officer (now Executive Chairman), Chief Financial Officer, former Chief Financial Officer and Chief Commercial Officer, and current and former members of the Board of Directors as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company’s prior public statements about revenues and internal controls were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board of Directors was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim does not quantify a damage request. (ii)Regulatory reviews relating to restatement The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019. The Company is responding to all such requests for information and cooperating with all regulatory authorities. The Company cannot predict the outcome of any such regulatory review or investigation and it is possible that additional investigations or one or more formal proceedings may be commenced against the Company and its current and former officers and directors in connection with these regulatory reviews and investigations. (iii)Litigation relating to marketing, distribution and sale of products On June 16, 2020, an alleged consumer filed a Statement of Claim on behalf of a class in the Court of Queen’s Bench of Alberta in Alberta, Canada, against the Company and other Canadian cannabis manufacturers and/or distributors. On December 4, 2020, a Third Amended Statement of Claim was filed, which added a second alleged consumer. The Third Amended Statement of Claim alleges claims related to the defendants’ advertised content of cannabinoids in cannabis products for medicinal use on or after June 16, 2010 and cannabis products for adult use on or after October 17, 2018. The Third Amended Statement of Claim seeks a total of C$500 million for breach of contract, compensatory damages, and unjust enrichment or such other amount as may be proven in trial and C$5 million in punitive damages against each defendant, including the Company. The Third Amended Statement of Claim also seeks interest and costs associated with the action. The Company has not responded to the Third Amended Statement of Claim. A number of claims, including purported class actions, have been brought in the U.S. against companies engaged in the U.S. hemp business alleging, among other things, violations of state consumer protection, health and advertising laws. On April 8, 2020, a putative class action complaint was filed in the U.S. District Court for the Central District of California against Redwood Holding Group, LLC (“Redwood”), alleging violations of California’s Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, and breaches of the California Commercial Code for breach of express warranties and implied warranty of merchantability with respect to Redwood’s marketing and sale of U.S. hemp products. The complaint did not quantify a damage request. On April 10, 2020, the class action complaint was dismissed for certain pleading deficiencies and the plaintiff was granted leave until April 24, 2020 to amend the complaint to establish federal subject matter jurisdiction. On April 28, 2020, the action was dismissed without prejudice for failure to prosecute and for failure to comply with a court order. As of the date of this Quarterly Report, the plaintiff has not refiled the complaint. The Company expects litigation and regulatory proceedings relating to the marketing, distribution and sale of its products to increase.

Financial Instruments

3 Months Ended

Mar. 31, 2021

Risks and Uncertainties [Abstract]

Financial Instruments

(a)Fair Value Measurement

The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by:

•Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.

•Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves.

•Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.

The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.


	March 31, 2021
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	1,024,450	$	—	$	—	$	1,024,450
Short-term investments	214,925		—		—		214,925
Derivative liabilities	—		—		272,300		272,300


	December 31, 2020
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	1,078,023	$	—	$	—	$	1,078,023
Short-term investments	211,766		—		—		211,766
Derivative liabilities	—		—		163,410		163,410

There were no transfers between categories during the periods presented.

(b)Financial Risks

The Company’s activities expose it to a variety of financial risks, including credit risk, market risk, interest rate risk, liquidity risk, and foreign currency rate risk.

(i)Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loan receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $1,348,325 and $1,403,491 as of March 31, 2021 and December 31, 2020, respectively.

(a)Cash and cash equivalents, short-term investments, and other receivables

The Company held cash and cash equivalents of $1,024,450 and $1,078,023 as of March 31, 2021 and December 31, 2020, respectively. The short-term investments and related interest receivable of $214,925 and $211,766, as of March 31, 2021 and December 31, 2020 respectively, represents short-term investments with a maturity of less than a year and accrued interest as of period end. The cash and cash equivalents and short-term investments, including guaranteed investment certificates and bankers’ acceptances, are held with central banks and financial institutions that are highly rated. In addition to interest receivable, other receivables include sales taxes receivable from the government. As such, the Company has assessed an insignificant loss allowance on these financial instruments.

(b)Accounts receivable

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, among others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of March 31, 2021 and December 31, 2020, the Company recorded a current expected credit loss allowance of $66 and $74, respectively. As of March 31, 2021, the Company has assessed that there is a concentration of credit risk, as 63% of the Company’s accounts receivable were due from three customers with an established credit history with the Company. As of December 31, 2020, 78% of the Company’s accounts receivable were due from four customers with an established credit history with the Company.

(ii)Market risk

Market risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in market prices. The value of financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to market risk in divesting its investments, such that unfavorable market conditions could result in dispositions of investments at less than their carrying values. Further, the revaluation of securities classified as fair value through net income could result in significant write-downs of the Company’s investments, which would have an adverse impact on the Company’s financial position, unless these would flow through other comprehensive income.

The Company manages market risk by having a portfolio of securities from multiple issuers so that the Company is not materially exposed to any one issuer.

(iii)Interest rate risk

Interest rate risk is the risk that the value or yield of fixed-income investments may decline if interest rates change. Fluctuations in interest rates may impact the level of income and expense recorded on the cash equivalents and short-term investments, and the market value of all interest-earning assets, other than those which possess a short-term to maturity. A 10% change in the interest rate in effect on March 31, 2021 and December 31, 2020 would not have a material effect on (i) fair value of the cash equivalents and short-term investments as the majority of the portfolio has a maturity date of three months or less or (ii) interest income. Management continues to monitor external interest rates and revise the Company’s investment strategy as a result.

During the three months ended March 31, 2021 and 2020, the Company had net interest income of $2,329 and $7,751, respectively.

(iv)Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due and arises principally from the Company’s accounts payable and other liabilities. The Company’s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company’s management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. The Company’s funding was primarily provided in the form of capital raised through the issuance of common shares and warrants. As of March 31, 2021, the Company had assessed a concentration risk of vendors as 26% of accounts payables were due to two vendors. As of December 31, 2020, the Company had assessed a concentration risk of vendors as 64% due to four vendors.

(v)Foreign currency risk

Currency rate risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to this risk on investments in equity investees denominated in dollars, A$ and C$, and other assets and liabilities denominated in A$ and C$. The Company is further exposed to this risk through subsidiaries operating in Israel and the U.S. as the Company’s functional currency is in Canadian dollars. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk. As such, the Company’s financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates.

During the three months ended March 31, 2021 and 2020, the Company had foreign currency gain (loss) on translation of $16,284 and $(113,692), respectively. A 10% change in the exchange rates for the U.S. dollar would affect the carrying value of net assets by approximately $156,828 and $170,817 as of March 31, 2021 and December 31, 2020, respectively.

Held-For-Sale Assets and Discontinued Operations

3 Months Ended

Mar. 31, 2021

Discontinued Operations and Disposal Groups [Abstract]

Held-For-Sale Assets and Discontinued Operations

During the year ended December 31, 2020, the Company advanced its plans for the sale and disposal of substantially all of the assets of Original B.C. Ltd. (“OGBC”) and as a result, OGBC’s results of operations were reclassified as discontinued operations in the accompanying condensed consolidated financial statements. As of March 31, 2021, the assets and liabilities of OGBC continue to meet the definition of discontinued operations and are included as “held-for-sale” assets on the condensed consolidated balance sheet as of March 31, 2021 and December 31, 2020, and loss from discontinued operations on the condensed consolidated statements of net income and comprehensive income for the three months ended March 31, 2021 and 2020.

During the three months ended March 31, 2021, the Company advanced its plans for the sale of land and office premises (approximately 80,173 combined square feet) located in Winnipeg, Manitoba, Canada and accounted for in the Rest of World segment. The sale is expected to be made within the next twelve months and the criteria for the land and office premises to be classified as “held-for-sale” were met during the three months ended March 31, 2021. As a result, the assets are classified as “held-for-sale” assets as of March 31, 2021.

The following table summarizes the financial information for discontinued operations:


	Three months ended March 31,
		2021		2020
Loss from discontinued operations, net of income taxes		$	(21)	$	—


	March 31, 2021		December 31, 2020
OGBC assets classified as held-for-sale	$	1,195	$	1,176
Other property, plant and equipment classified as held-for-sale	774		—
Held-for-sale assets	$	1,969	$	1,176

Related Party Transactions and Balances	3 Months Ended
Related Party Transactions and Balances	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions and Balances	Related Party Transactions and BalancesThere have been no material related party transactions during the three months ended March 31, 2021 and 2020. As of March 31, 2021 and December 31, 2020 there were no material related party receivables or payables.

Impairment Loss on Property, Plant and Equipment and Right-of-Use Assets	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Impairment Loss on Property, Plant and Equipment and Right-of-Use Assets	Impairment Loss on Property, Plant and Equipment and Right-of-Use AssetsDuring the three months ended March 31, 2021, the Company recognized an impairment charge of $1,019 related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. The significant change in the extent and manner in which the leasehold improvements are being used and the expectation that, more likely than not, the leasehold improvements will be disposed of before the end of their useful life triggered an impairment. The right-of-use lease asset associated with the leasehold improvements was also written down as a result of our decision to no longer use the leased premises. The Company recognized an impairment charge on the de-recognition of the right-of-use asset of $702 during the three months ended March 31, 2021. Both the impairment charges are recognized in the statement of net income (loss) as an impairment loss on property, plant and equipment and right-of-use assets.

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn April 1, 2021, the Company and an affiliate of Agroidea (“AGI”), the other joint venture partner of Natuera, agreed to convert all advances made to Natuera under the Series A Loan, plus accrued interest, into equity. Total aggregate gross advances to Natuera under the Series A Loan were $15,500, of which the Company advanced 50% and AGI advanced the remaining 50%, for an amount of $7,750 each. As a result, the Company transferred the carrying value of the loan of $2,013 plus accrued interest, which approximates fair value, to investments in equity accounted investees in respect of Natuera.

Background, Basis of Presentation and Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The interim condensed consolidated financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Annual Financial Statements”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated financial statements. These reclassifications had no effect on the reported results of operations and ending shareholder’s equity.
Adoption of new accounting pronouncements and New accounting pronouncements not yet adopted	Adoption of new accounting pronouncements On January 1, 2021, the Company adopted ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU No. 2020-01”). ASU No. 2020-01 clarifies the interaction of accounting for the transition into and out of the equity method as well as measuring certain purchased options and forwards contracts to acquire investments. The adoption of ASU No. 2020-01 did not have an impact on the Company’s interim condensed consolidated financial statements. On January 1, 2021, the Company adopted ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). ASU No. 2019-12 eliminates certain exceptions and simplifies the application of U.S. GAAP-related changes in enacted tax laws or rates and employee stock option plans. The adoption of ASU No. 2019-12 did not have an impact on the Company’s interim condensed consolidated financial statements. (e)New accounting pronouncements not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging –Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU No. 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU No. 2020-06 will have on its interim condensed consolidated financial statements.

Inventory, net (Tables)

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory, net is comprised of the following items:


	As of March 31, 2021		As of December 31, 2020
Raw materials, net	$	11,182	$	11,489
Work-in-progress – dry cannabis, net	21,590		20,520
Work-in-progress – cannabis extracts, net	5,036		5,758
Finished goods – dry cannabis, net	5,677		4,894
Finished goods – cannabis extracts, net	2,141		1,011
Supplies and consumables	811		330
Total	$	46,437	$	44,002

Investments in Equity Accounted Investees, net (Tables)

3 Months Ended

Mar. 31, 2021

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Equity Method Investments

A reconciliation of the carrying amount of the investments in associates and joint ventures is as follows:


	Ownership interest	As of March 31, 2021		As of December 31, 2020
Cronos Australia	31%	$	—	$	—
Cronos GrowCo	50%	$	19,221	$	19,235
Natuera	50%	—		—
		$	19,221	$	19,235

The Company’s share of net earnings (losses) from equity investments accounted for under the equity method of accounting:


	For the three months ended March 31,
		2021		2020



Cronos GrowCo		$	(299)	$	(311)

Natuera(i)		(1,344)		(861)

		$	(1,643)	$	(1,172)

(i) The Company’s share of accumulated net losses in excess of its equity investment in Natuera has been applied as a loss allowance on the loan receivable. See Note 4. Loans Receivable, net.

Schedule of Variable Interest Entities

The following is a summary of the maximum exposure to loss as of March 31, 2021 and December 31, 2020:


	Ownership interest	As of March 31, 2021			As of December 31, 2020
Cronos Australia	31%		$	1,553	$	1,530
Cronos GrowCo	50%		21,433		21,125
MedMen Canada	50%		487		467
Natuera	50%		8,160		8,154
Total			$	31,633	$	31,276

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

Loans Receivable, net (Tables)

3 Months Ended

Mar. 31, 2021

Receivables [Abstract]

Schedule of Loan Receivable


	As of March 31, 2021		As of December 31, 2020
Natuera Series A loan(i)	$	2,013	$	3,518
GrowCo Facility(ii)	796		3,137
Add: Accrued interest	3,908		428
Total current portion of loans receivable	6,717		7,083
GrowCo Facility(ii)	76,043		69,939
Mucci promissory note(iii)	13,654		13,324
Cannasoul collaboration loan(iv)	1,215		1,261
Add: Accrued interest	41		2,667
Total long-term portion of loans receivable	90,953		87,191
Total loans receivable, net	$	97,670	$	94,274

(iii)As of March 31, 2021 and December 31, 2020, a current expected credit loss allowance of $274 and $259, respectively, was recorded against the Mucci promissory note.

Derivative Liabilities (Tables)

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Reconciliation of Carrying Amounts

A reconciliation of the carrying amounts of the derivative liability for the three months ended March 31, 2021 and 2020:


	As of January 1, 2021		Revaluation (gain)/loss		Exercise of rights		Foreign exchange effect		As of March 31, 2021
(a) Altria Warrant	$	138,858	$	92,964	$	—	$	2,834	$	234,656
(b) Pre-emptive Rights	12,095		7,833		—		245		20,173
(c) Top-up Rights	12,457		16,077		(11,278)		215		17,471
	$	163,410	$	116,874	$	(11,278)	$	3,294	$	272,300


	As of January 1, 2020		Revaluation (gain)/loss		Exercise of rights		Foreign exchange effect		As of March 31, 2020
(a) Altria Warrant	$	234,428	$	(88,104)	$	—	$	(13,958)	$	132,366
(b) Pre-emptive Rights	12,787		1,315		—		(1,032)		13,070
(c) Top-up Rights	49,945		(26,579)		—		(2,626)		20,740
	$	297,160	$	(113,368)	$	—	$	(17,616)	$	166,176

Schedule of Fair Values of Derivative Liabilities

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model as of March 31, 2021 and December 31, 2020 applying the following inputs:


	As of March 31, 2021			As of December 31, 2020
	Altria Warrant	Pre-emptive Rights	Top-up Rights	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price at valuation date (i)	$11.88	$11.88	$11.88	$8.84	$8.84	$8.84
Subscription price (i)	$19.00	$16.25	$16.25	$19.00	$16.25	$16.25
Weighted average risk-free interest rate (ii)	0.22%	0.17%	0.14%	0.21%	0.17%	0.13%
Weighted average expected life (iii)	1.93	1.25	0.72	2.18	1.50	0.98
Expected annualized volatility (iv)	82%	82%	82%	81%	81%	81%
Expected dividend yield	—%	—%	—%	—%	—%	—%

(i)Per share in C$.

Schedule of Sensitivity Analysis


	Increase as of March 31, 2021
	Altria Warrant		Pre-emptive Rights		Top-up Rights
Share price	$	42,479	$	4,133	$	4,376
Weighted average expected life	18,051		3,039		683
Expected annualized volatility	35,099		2,865		2,785

Share-based Payments (Tables)

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Summary of Stock-based Compensation Expense

The following table summarizes the total stock-based compensation expense associated with the Company’s stock options and RSUs for the three months ended March 31, 2021 and 2020:


	For the three months ended March 31,
	2021		2020
Vesting of stock options	$	2,064	$	1,730
Vesting of RSUs	435		706
Total share-based payments	$	2,499	$	2,436

Summary of the Changes in Options

The following is a summary of the changes during the three months ended March 31, 2021 and 2020:


	Weighted average exercise price (C$) (i)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2021	$	5.40	13,755,148	2.30

Exercise of options	2.13		(5,230,550)
Cancellation, forfeiture and expiry of options	14.71		(25,771)
Balance as of March 31, 2021	$	7.38	8,498,827	2.82
Exercisable as of March 31, 2021	$	5.75	4,896,820	1.46

(i)The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.


	Weighted average exercise price (C$)		Number of options	Weighted average remaining contractual term (years)
Balance as of January 1, 2020	$	4.84	14,149,502	2.56


Cancellation, forfeiture and expiry of options	17.17		(42,889)
Balance as of March 31, 2020	$	4.80	14,106,613	2.06
Exercisable as of March 31, 2020	$	3.11	9,783,544	1.66

The following table summarizes stock options outstanding for the 2020 Omnibus Plan, the 2018 Stock Option Plan, and the 2015 Stock Option Plan:


	Stock options outstanding as of
	March 31, 2021	December 31, 2020
2020 Omnibus Plan	2,000,000	2,000,000
2018 Stock Option Plan	1,591,944	1,627,715
2015 Stock Option Plan	4,906,883	10,127,433
Total stock options outstanding	8,498,827	13,755,148

Summary of Changes in RSUs

The following is a summary of the changes in RSUs for the three months ended March 31, 2021 and 2020:


	Number of RSUs (i)	Weighted average grant date fair value (C$) (ii)
Balance as of January 1, 2021	948,357	$	7.66
Granted(i)	265,904	13.27


Balance as of March 31, 2021	1,214,261	$	8.89

(ii)The weighted average exercise price reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.


	Number of RSUs	Weighted average grant date fair value (C$)
Balance as of January 1, 2020 and March 31, 2020	732,972	$	15.34

Summary of Changes in DSUs and Warrants

The following is a summary of the changes in DSUs during the three months ended March 31, 2021 and 2020:


	Number of DSUs	Financial liability
Balance as of January 1, 2021	83,293	$	577


Loss (gain) on revaluation	—	211
Balance as of March 31, 2021	83,293	$	788


	Number of DSUs	Financial liability
Balance as of January 1, 2020	33,937	$	255


Loss (gain) on revaluation	—	(50)
Balance as of March 31, 2020	33,937	$	205

The following is a summary of the changes in warrants during the three months ended March 31, 2021 and 2020:


	Weighted average exercise price (C$)		Number of warrants
Balance as of January 1, 2021	$	0.25	7,987,349
Exercise of warrants	0.25		(7,977,349)

Balance as of March 31, 2021(i)	$	0.25	10,000

(i)The outstanding warrants were granted in the second quarter of 2016 and expire on May 27, 2021.


	Weighted average exercise price (C$)		Number of warrants
Balance as of January 1, 2020 and March 31, 2020	$	0.26	18,066,662

Earnings (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Schedule of Earnings (Loss) Per Share

Basic and diluted earnings (loss) per share from continuing operations are calculated using the following numerators and denominators:


	For the three months ended March 31,
	2021		2020
Basic earnings per share computation
Net income (loss) attributable to common shareholders of Cronos Group	$	(161,312)	$	76,040
Weighted average number of common shares outstanding	363,012,740		348,817,472
Basic earnings per share(i)	$	(0.44)	$	0.22
Diluted earnings per share computation
Net income (loss) used in the computation of basic earnings per share	$	(161,312)	$	76,040
Adjustment for gain (loss) on revaluation of derivative liabilities	—		—
Net income (loss) used in the computation of diluted income per share	$	(161,312)	$	76,040

Weighted average number of common shares outstanding used in the computation of basic earnings per share	363,012,740		348,817,472
Dilutive effect of warrants	—		17,550,444
Dilutive effect of stock options	—		7,962,252



Weighted average number of common shares for computation of diluted income (loss) per share	363,012,740		374,330,168
Diluted earnings per share(i)	$	(0.44)	$	0.20

(i)Basic and dilutive earnings per share from discontinued operations were $0.00 and $0.00 for the three months ended March 31, 2021 and 2020, respectively.

Schedule of Antidilutive Securities Excluded from Computation of Diluted Shares Outstanding


	Three months ended March 31,
	2021	2020
Ginkgo equity milestones	14,674,904	14,674,904
Pre-emptive Rights	11,285,001	12,006,740
Top-up Rights – fixed price	11,113,451	25,111,456
Top-up Rights – market price	2,623,082	1,941,349
Altria Warrant	82,590,353	77,514,993
Stock options	8,522,086	2,240,456
Warrants	5,563,176	—
Restricted share units	572,970	732,972
Total anti-dilutive securities	136,945,023	134,222,870

Segment Information (Tables)

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Schedule of Segment Data and Adjusted EBITDA

Segment data was as follows for the three months ended March 31, 2021 and 2020:


	Three months ended March 31, 2021
	United States		Rest of World		Corporate expenses		Total
Net revenue
Cannabis flower	$	—	$	9,434	$	—	$	9,434
Cannabis extracts	2,441		703		—		3,144
Other	—		33		—		33
Net revenue	$	2,441	$	10,170	$	—	$	12,611

Share of loss from investments in equity accounted investees	$	—	$	1,643	$	—	$	1,643

Interest income	3		2,332		—		2,335
Interest expense	—		(6)		—		(6)
Interest income, net	$	3	$	2,326	$	—	$	2,329

Depreciation and amortization	$	71	$	664	$	—	$	735
Impairment loss on property, plant and equipment and right-of-use assets	1,741		—		—		1,741
Loss from discontinued operations	—		21		—		21
Adjusted EBITDA	(9,510)		(22,184)		(5,381)		(37,075)

Total assets	252,449		394,442		1,234,391		1,881,282
Investments in equity accounted investees	—		19,221		—		19,221
Goodwill	178,416		1,115		—		179,531
Purchase of property, plant and equipment, net	80		6,600		—		6,680


	Three months ended March 31, 2020
	United States		Rest of World		Corporate expenses		Total
Net revenue
Cannabis flower	$	—	$	2,741	$	—	$	2,741
Cannabis extracts	2,176		3,400		—		5,576
Other	—		115		—		115
Net revenue	$	2,176	$	6,256	$	—	$	8,432

Share of loss from investments in equity accounted investees	$	—	$	1,172	$	—	$	1,172

Interest income	7		7,751		—		7,758
Interest expense	—		(7)		—		(7)
Interest income, net	$	7	$	7,744	$	—	$	7,751

Depreciation and amortization	33		654		—		687

Adjusted EBITDA	$	(5,782)	$	(29,010)	$	(2,263)	$	(37,055)

Adjusted EBITDA is reconciled to net income (loss) as follows for the three months ended March 31, 2021 and 2020:


(In thousands of U.S. dollars)	Three months ended March 31, 2021
	US		ROW		Corporate Expenses		Total
Net income (loss)	$	(12,092)	$	(142,147)	$	(7,386)	$	(161,625)
Adjustments
Interest income, net	(3)		(2,326)		—		(2,329)


Impairment loss on property, plant and equipment and right-of-use assets	1,741		—		—		1,741
Loss on revaluation of derivative liabilities	—		116,874		—		116,874

Other loss	—		1,859		—		1,859
Loss from discontinued operations	—		21		—		21
Share-based payments	745		1,754		—		2,499
Review costs related to restatement of 2019 interim financial statements	—		—		2,005		2,005
Adjusted EBIT	(9,609)		(23,965)		(5,381)		(38,955)
Adjustments
Depreciation and amortization	99		1,781		—		1,880
Adjusted EBITDA	$	(9,510)	$	(22,184)	$	(5,381)	$	(37,075)


(In thousands of U.S. dollars)	Three months ended March 31, 2020
	US		ROW		Corporate Expenses		Total
Net income (loss)	$	(6,516)	$	88,867	$	(6,670)	$	75,681
Adjustments
Interest income, net	(7)		(7,744)		—		(7,751)


Gain on revaluation of derivative liabilities	—		(113,368)		—		(113,368)
Other loss	—		378		—		378

Share-based payments	706		1,730		—		2,436
Review costs related to restatement of 2019 interim financial statements	—		—		4,407		4,407
Adjusted EBIT	(5,817)		(30,137)		(2,263)		(38,217)
Adjustments
Depreciation and amortization	35		1,127		—		1,162
Adjusted EBITDA	$	(5,782)	$	(29,010)	$	(2,263)	$	(37,055)

Sources of net revenue for the three months ended March 31, 2021 and 2020 were as follows:


	Three months ended March 31,
		2021		2020
Cannabis flower		$	9,434	$	2,741
Cannabis extracts		3,144		5,576
Other		33		115
Net revenue		$	12,611	$	8,432

Schedule of Revenue from External Customers by Geographic Areas

Net revenue attributed to a geographic region based on the location of the customer were as follows:


	Three months ended March 31,
		2021		2020
Canada		$	7,582	$	6,091
Israel		2,518		—
United States		2,441		2,176
Other countries		70		165
Net revenue		$	12,611	$	8,432

Schedule of Long-lived Assets by Geographic Areas

Property, plant and equipment assets were physically located in the following geographic regions:


	As of March 31, 2021		As of December 31, 2020
Canada	$	167,363	$	162,163
Israel	23,480		23,143
United States	1,280		2,293

Total	$	192,123	$	187,599

Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2021

Risks and Uncertainties [Abstract]

Schedule of Fair Value of Assets Measured on Recurring Basis


	March 31, 2021
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	1,024,450	$	—	$	—	$	1,024,450
Short-term investments	214,925		—		—		214,925
Derivative liabilities	—		—		272,300		272,300


	December 31, 2020
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	1,078,023	$	—	$	—	$	1,078,023
Short-term investments	211,766		—		—		211,766
Derivative liabilities	—		—		163,410		163,410

Held-For-Sale Assets and Discontinued Operations (Tables)

3 Months Ended

Mar. 31, 2021

Discontinued Operations and Disposal Groups [Abstract]

Summary of Financial Information for Discontinued Operations

The following table summarizes the financial information for discontinued operations:


	Three months ended March 31,
		2021		2020
Loss from discontinued operations, net of income taxes		$	(21)	$	—


	March 31, 2021		December 31, 2020
OGBC assets classified as held-for-sale	$	1,195	$	1,176
Other property, plant and equipment classified as held-for-sale	774		—
Held-for-sale assets	$	1,969	$	1,176

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Background, Basis of Presentation and Accounting Policies (Details)
$ in Thousands

Mar. 31, 2021

USD ($)

continent

brand

Dec. 31, 2020

USD ($)

Schedule of Equity Method Investments [Line Items]

Number of continents with international production and distribution | continent

Number of adult-use brands | brand

Number of hemp-derived cannabidiol personal care brands | brand

Accounts payable and other liabilities

$ 29,213

$ 42,102

Other receivables

3,796

10,033

Retained earnings

895,503

1,064,509

Share capital

^[1],[2]

$ 584,912

569,260

Error Correction, Adjustment

Schedule of Equity Method Investments [Line Items]

Accounts payable and other liabilities

966

(3,202)

(3,838)

$ (330)

Schedule of Equity Method Investments [Line Items]

Ownership interest

31.00%

[1]	Authorized for issuance as of March 31, 2021: unlimited and December 31, 2020: unlimited.
[2]	Shares issued as of March 31, 2021: 371,656,590 and December 31, 2020: 360,253,332

Inventory, net (Details) - USD ($)	3 Months Ended
Inventory, net (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Inventory [Line Items]
Raw materials, net	$ 11,182,000		$ 11,489,000
Supplies and consumables	811,000		330,000
Inventory, net	46,437,000		44,002,000
Inventory write-down	0	$ 7,962,000
Dry Cannabis
Inventory [Line Items]
Work-in-progress	21,590,000		20,520,000
Finished goods	5,677,000		4,894,000
Cannabis Extracts
Inventory [Line Items]
Work-in-progress	5,036,000		5,758,000
Finished goods	$ 2,141,000		$ 1,011,000

Investments in Equity Accounted Investees, net - Narrative (Details) - Variable Interest Entity, Not Primary Beneficiary ₪ in Thousands, $ in Thousands			3 Months Ended
	Jun. 14, 2018	Mar. 13, 2018	Mar. 31, 2021 USD ($)	Mar. 31, 2021 ILS (₪)
Cronos GrowCo
Variable Interest Entity [Line Items]
Ownership percentage	50.00%		50.00%
MedMen Canada
Variable Interest Entity [Line Items]
Ownership percentage		50.00%	50.00%
Natuera
Variable Interest Entity [Line Items]
Ownership percentage			50.00%
Cannasoul \| Establishment of a Commercial Cannabis Analytical Testing Laboratory
Variable Interest Entity [Line Items]
Collaboration agreement, percentage of profits to be received			70.00%	70.00%
Collaboration agreement, profits to be received, maximum percentage of amounts advanced			150.00%	150.00%
Collaboration agreement, percentage of profits to be received, triggering event, subsequent to maximum percentage of amounts advanced being met			50.00%	50.00%
Cannasoul \| Establishment of a Commercial Cannabis Analytical Testing Laboratory \| Cannasoul collaboration loan \| Loans Receivable
Variable Interest Entity [Line Items]
Collaboration agreement, amount of advances			$ 2,483	₪ 8,297
Collaboration agreement, term of agreement			2 years
Interest rate			3.50%	3.50%
Minimum \| MedMen Canada
Variable Interest Entity [Line Items]
License term		20 years

Investments in Equity Accounted Investees, net - Schedule of Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Investments in equity accounted investees, net	$ 19,221		$ 19,235
Share of earnings (loss) from investments in equity accounted investees	$ (1,643)	$ (1,172)
Cronos Australia
Schedule of Equity Method Investments [Line Items]
Ownership interest	31.00%
Investments in equity accounted investees, net	$ 0		0
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Investments in equity accounted investees, net	$ 19,221		19,235
Share of earnings (loss) from investments in equity accounted investees	$ (299)	(311)
Natuera
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Investments in equity accounted investees, net	$ 0		$ 0
Share of earnings (loss) from investments in equity accounted investees	$ (1,344)	$ (861)

Investments in Equity Accounted Investees, net - Schedule of Variable Interest Entities (Details) - USD ($) $ in Thousands			3 Months Ended
	Jun. 14, 2018	Mar. 13, 2018	Mar. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Maximum Exposure to Loss			$ 31,633	$ 31,276
Cronos Australia \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest			31.00%
Maximum Exposure to Loss			$ 1,553	1,530
Cronos GrowCo \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest	50.00%		50.00%
Maximum Exposure to Loss			$ 21,433	21,125
MedMen Canada \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest		50.00%	50.00%
Maximum Exposure to Loss			$ 487	467
Natuera \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest			50.00%
Maximum Exposure to Loss			$ 8,160	$ 8,154

Loans Receivable, net (Details)
₪ in Thousands, $ in Thousands, $ in Thousands

3 Months Ended

Mar. 31, 2021

USD ($)

Mar. 31, 2021

CAD ($)

Mar. 31, 2020

USD ($)

Mar. 31, 2020

CAD ($)

Mar. 31, 2021

ILS (₪)

Dec. 31, 2020

USD ($)

Dec. 31, 2020

ILS (₪)

Accounts, Notes, Loans and Financing Receivable [Line Items]

Total current portion of loans receivable

^[1]

$ 6,717

$ 7,083

Total long-term portion of loans receivable

90,953

87,191

Draw downs

2,645

$ 14,512

Current expected credit loss allowance on accounts receivable

Loans Receivable

Accounts, Notes, Loans and Financing Receivable [Line Items]

Add: Accrued interest

3,908

428

Total current portion of loans receivable

6,717

7,083

Add: Accrued interest

2,667

Total long-term portion of loans receivable

90,953

87,191

Total loans receivable, net

97,670

94,274

NatuEra Series A Loan | Loans Receivable

Accounts, Notes, Loans and Financing Receivable [Line Items]

Current portion of loans receivable, before accrued interest

2,013

3,518

Allowance for credit loss

1,151

685

GrowCo Facility | Loans Receivable

Accounts, Notes, Loans and Financing Receivable [Line Items]

Current portion of loans receivable, before accrued interest

796

3,137

Long term portion of loans receivable, before accrued interest

76,043

69,939

Allowance for credit loss

1,569

1,470

Draw downs

78,405

$ 98,500

$ 74,626

$ 95,150

Mucci promissory note | Loans Receivable

Accounts, Notes, Loans and Financing Receivable [Line Items]

Long term portion of loans receivable, before accrued interest

13,654

13,324

Allowance for credit loss

274

259

Cannasoul collaboration loan | Loans Receivable

Accounts, Notes, Loans and Financing Receivable [Line Items]

Long term portion of loans receivable, before accrued interest

1,215

1,261

Cannasoul collaboration loan | Loans Receivable | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Cannasoul | Variable Interest Entity, Not Primary Beneficiary

Accounts, Notes, Loans and Financing Receivable [Line Items]

Collaborative arrangement, installment received

1,241

₪ 4,149

1,241

₪ 4,149

Current expected credit loss allowance on accounts receivable

NatuEra Series A Loan - Share Of Net Loss In Excess Of Carrying Value Of Equity Investment | Loans Receivable

Accounts, Notes, Loans and Financing Receivable [Line Items]

Allowance for credit loss

$ 4,582

$ 3,024

[1]	Net of current expected credit loss allowance on loans receivable of $3,020 and $2,439 as of March 31, 2021 and December 31, 2020, respectively.

Derivative Liabilities - Narrative (Details) $ in Thousands		3 Months Ended
Derivative Liabilities - Narrative (Details) $ in Thousands	Mar. 08, 2019 warrant day $ / shares shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2020 USD ($)
Derivative [Line Items]
Gain (loss) on revaluation		$ (116,874)	$ 113,368
Altria Group, Inc. \| Cronos Group, Inc.
Derivative [Line Items]
Ownership interest	45.00%
Altria Investment
Derivative [Line Items]
Shares issued (in shares) \| shares	149,831,154
Cronos Group, Inc. \| Altria Group, Inc.
Derivative [Line Items]
Ownership percentage, if warrant exercised	55.00%
Altria Investment
Derivative [Line Items]
Maximum additional subscription percentage	10.00%
Derivative liability, additional subscription (in shares) \| shares		82,600,000
Altria Warrant
Derivative [Line Items]
Number of warrants issued \| warrant	1
Exercise price (in dollars per share) \| $ / shares	$ 19.00
Gain (loss) on revaluation		$ (92,964)	88,104
Pre-emptive Rights
Derivative [Line Items]
Exercise price (in dollars per share) \| $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Gain (loss) on revaluation		(7,833)	(1,315)
Top-up Rights
Derivative [Line Items]
Exercise price (in dollars per share) \| $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Exercise price, volume-weighted average price, measurement period	10 days
Exercise price, volume-weighted average price, measurement period, days preceding exercise \| day	10
Gain (loss) on revaluation		$ (16,077)	$ 26,579

Derivative Liabilities - Schedule of Reconciliation of Carrying Amounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Derivative Instruments [Roll Forward]
Beginning balance	$ 163,410	$ 297,160
Revaluation (gain)/loss	116,874	(113,368)
Exercise of rights	(11,278)	0
Foreign exchange effect	3,294	(17,616)
Ending balance	272,300	166,176
Altria Warrant
Derivative Instruments [Roll Forward]
Beginning balance	138,858	234,428
Revaluation (gain)/loss	92,964	(88,104)
Exercise of rights	0	0
Foreign exchange effect	2,834	(13,958)
Ending balance	234,656	132,366
Pre-emptive Rights
Derivative Instruments [Roll Forward]
Beginning balance	12,095	12,787
Revaluation (gain)/loss	7,833	1,315
Exercise of rights	0	0
Foreign exchange effect	245	(1,032)
Ending balance	20,173	13,070
Top-up Rights
Derivative Instruments [Roll Forward]
Beginning balance	12,457	49,945
Revaluation (gain)/loss	16,077	(26,579)
Exercise of rights	(11,278)	0
Foreign exchange effect	215	(2,626)
Ending balance	$ 17,471	$ 20,740

Derivative Liabilities - Schedule of Fair Values of Derivative Liabilities (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares
Altria Warrant \| Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	11.88	8.84
Altria Warrant \| Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	19.00	19.00
Altria Warrant \| Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.82	0.81
Altria Warrant \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Altria Warrant \| Weighted Average \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0022	0.0021
Altria Warrant \| Weighted Average \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 11 months 4 days	2 years 2 months 4 days
Pre-emptive Rights \| Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	11.88	8.84
Pre-emptive Rights \| Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Pre-emptive Rights \| Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.82	0.81
Pre-emptive Rights \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Pre-emptive Rights \| Weighted Average \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0017	0.0017
Pre-emptive Rights \| Weighted Average \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 3 months	1 year 6 months
Top-up Rights \| Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	11.88	8.84
Top-up Rights \| Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Top-up Rights \| Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.82	0.81
Top-up Rights \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Top-up Rights \| Weighted Average \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0014	0.0013
Top-up Rights \| Weighted Average \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	8 months 19 days	11 months 23 days
Pre-emptive Rights and Top-up Rights \| Minimum \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0009	0.0010
Pre-emptive Rights and Top-up Rights \| Minimum \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	3 months	6 months
Pre-emptive Rights and Top-up Rights \| Maximum \| Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0086	0.0039
Pre-emptive Rights and Top-up Rights \| Maximum \| Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	4 years 6 months	5 years

Derivative Liabilities - Schedule of Sensitivity Analysis (Details) $ in Thousands	Mar. 31, 2021 USD ($)
Altria Warrant
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	$ 42,479
Weighted average expected life	18,051
Expected annualized volatility	35,099
Pre-emptive Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	4,133
Weighted average expected life	3,039
Expected annualized volatility	2,865
Top-up Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	4,376
Weighted average expected life	683
Expected annualized volatility	$ 2,785

Share-based Payments - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	$ 2,499	$ 2,436
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	2,064	1,730
Restricted share units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	$ 435	$ 706

Share-based Payments - Stock Options Narrative (Details) - Stock options	Mar. 29, 2020
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	7 years
Minimum \| 2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Minimum \| Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum \| 2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Maximum \| Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Share-based Payments - Summary of the Changes in Options (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2021 $ / shares $ / shares shares	Mar. 31, 2020 $ / shares $ / shares shares	Dec. 31, 2020 $ / shares shares	Dec. 31, 2019 $ / shares shares
Weighted average exercise price (C$)
Balance at beginning of period (in dollars per share) \| $ / shares	$ 5.40	$ 4.84	$ 4.84
Exercise of options (in dollars per share) \| $ / shares	2.13
Cancellation, forfeiture and expiry of options (in dollars per share) \| $ / shares	14.71	17.17
Balance at end of period (in dollars per share) \| $ / shares	$ 7.38	$ 4.80	$ 5.40	$ 4.84
Weighted average exercise price of options exercisable (in dollars per share) \| $ / shares	$ 5.75	$ 3.11
Number of options
Balance at beginning of period (in shares) \| shares	13,755,148	14,149,502	14,149,502
Exercise of options (in shares) \| shares	(5,230,550)
Cancellation, forfeiture and expiry of options (in shares) \| shares	(25,771)	(42,889)
Balance at end of period (in shares) \| shares	8,498,827	14,106,613	13,755,148	14,149,502
Exercisable (in shares) \| shares	4,896,820	9,783,544
Weighted average remaining contractual term (years)
Outstanding	2 years 9 months 25 days	2 years 21 days	2 years 3 months 18 days	2 years 6 months 21 days
Exercisable	1 year 5 months 15 days	1 year 7 months 28 days

Share-based Payments - Schedule of Stock Options Outstanding (Details) - shares	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options (in shares)	8,498,827	13,755,148	14,106,613	14,149,502
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options (in shares)	2,000,000	2,000,000
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options (in shares)	1,591,944	1,627,715
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options (in shares)	4,906,883	10,127,433

Share-based Payments - Summary of Changes in RSUs (Details) - Restricted share units - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Number of awards
Balance at beginning of period (in shares)	948,357	732,972
Granted (in shares)	265,904
Balance at end of period (in shares)	1,214,261	732,972
Weighted average grant date fair value (C$)
Balance at beginning of period (in dollars per share)	$ 7.66	$ 15.34
Granted (in dollars per share)	13.27
Balance at end of period (in dollars per share)	$ 8.89	$ 15.34
2020 Omnibus Plan
Weighted average grant date fair value (C$)
Vesting period	3 years	3 years

Share-based Payments - Summary of Deferred Share Units Activity (Details) - Deferred Share Units (DSUs) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Number of awards
Balance at beginning of period (in shares)	83,293	33,937
Balance at end of period (in shares)	83,293	33,937
Financial liability
Balance at beginning of period	$ 577	$ 255
Loss (gain) on revaluation	211	(50)
Balance at end of period	$ 788	$ 205

Share-based Payments - Summary of Changes in Warrants (Details) - Warrants	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Weighted average exercise price (C$)
Balance at beginning of period (in dollars per share) \| $ / shares	$ 0.25
Exercise of warrants (in dollars per share) \| $ / shares	0.25
Balance at end of period (in dollars per share) \| $ / shares	$ 0.25
Number of awards
Balance at beginning of period (in shares) \| shares	7,987,349
Exercise of warrants (in shares) \| shares	(7,977,349)
Balance at end of period (in shares) \| shares	10,000

Share-based Payments - Summary of Outstanding Warrants (Details) - Warrants - $ / shares	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price (in dollars per share)	$ 0.25	$ 0.25	$ 0.26	$ 0.26
Number of warrants (in shares)	10,000	7,987,349	18,066,662	18,066,662

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Basic earnings per share computation
Net income (loss) attributable to common shareholders of Cronos Group	$ (161,312)	$ 76,040
Weighted average number of common shares outstanding (in shares)	363,012,740	348,817,472
Basic earnings per share (in dollars per share)	$ (0.44)	$ 0.22
Diluted earnings per share computation
Net income (loss) used in the computation of basic earnings per share	$ (161,312)	$ 76,040
Adjustment for gain (loss) on revaluation of derivative liabilities	0	0
Net income (loss) used in the computation of diluted income per share	$ (161,312)	$ 76,040
Weighted average number of common shares outstanding (in shares)	363,012,740	348,817,472
Weighted average number of common shares for computation of diluted income (loss) per share (in shares)	363,012,740	374,330,168
Diluted earnings per share (in dollars per share)	$ (0.44)	$ 0.20
Basic earnings per share - discontinued operations (in dollars per share)	0.00	0.00
Diluted earnings per share - discontinued operations (in dollars per share)	$ 0.00	$ 0.00
Warrants
Diluted earnings per share computation
Dilutive effect of awards (in shares)	0	17,550,444
Stock options
Diluted earnings per share computation
Dilutive effect of awards (in shares)	0	7,962,252

Earnings (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Shares Outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	136,945,023	134,222,870
Ginkgo equity milestones
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	14,674,904	14,674,904
Pre-emptive Rights
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	11,285,001	12,006,740
Top-up Rights – fixed price
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	11,113,451	25,111,456
Top-up Rights – market price
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	2,623,082	1,941,349
Altria Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	82,590,353	77,514,993
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	8,522,086	2,240,456
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	5,563,176	0
Restricted share units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	572,970	732,972

Segment Information - Narrative (Details)	3 Months Ended
Segment Information - Narrative (Details)	Mar. 31, 2021 USD ($) segment	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| segment	2
Current expected credit loss allowance on accounts receivable	$ 66,000		$ 74,000
Net revenue, before excise taxes	14,654,000	$ 9,344,000
Loss from discontinued operations	21,000	0
United States
Segment Reporting Information [Line Items]
Current expected credit loss allowance on accounts receivable	36,000		65,000
Rest of World
Segment Reporting Information [Line Items]
Current expected credit loss allowance on accounts receivable	30,000		$ 9,000
Loss from discontinued operations	21,000	0
Four Major Customers \| Rest of World
Segment Reporting Information [Line Items]
Net revenue, before excise taxes	$ 8,963,000
Customer Concentration Risk \| Revenue Benchmark \| Societe Quebecoise Du Cannabis \| Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage	18.00%
Customer Concentration Risk \| Revenue Benchmark \| Novolog Group \| Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage	17.00%
Customer Concentration Risk \| Revenue Benchmark \| Albert Gaming, Liquor and Cannabis Commission \| Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage	13.00%
Customer Concentration Risk \| Revenue Benchmark \| Ontario Cannabis Retail Corporation \| Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage	13.00%
Customer Concentration Risk \| Revenue Benchmark \| Three Major Customers \| Rest of World
Segment Reporting Information [Line Items]
Net revenue, before excise taxes		$ 4,121,000
Concentration risk, percentage		49.00%

Segment Information - Schedule of Segment Data (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Net revenue
Net revenue	$ 12,611,000	$ 8,432,000
Share of loss from investments in equity accounted investees	1,643,000	1,172,000
Interest income	2,335,000	7,758,000
Interest expense	(6,000)	(7,000)
Interest income, net	2,329,000	7,751,000
Depreciation and amortization	735,000	687,000
Impairment loss on property, plant and equipment and right-of-use assets	1,741,000
Loss from discontinued operations	21,000	0
Adjusted EBITDA	(37,075,000)	(37,055,000)
Total assets	1,881,282,000		$ 1,925,682,000
Investments in equity accounted investees	19,221,000		19,235,000
Goodwill	179,531,000		$ 179,522,000
Purchase of property, plant and equipment, net	6,680,000
Rest of World
Net revenue
Loss from discontinued operations	21,000	0
Operating Segments \| United States
Net revenue
Net revenue	2,441,000	2,176,000
Share of loss from investments in equity accounted investees	0	0
Interest income	3,000	7,000
Interest expense	0	0
Interest income, net	3,000	7,000
Depreciation and amortization	71,000	33,000
Impairment loss on property, plant and equipment and right-of-use assets	1,741,000
Loss from discontinued operations	0
Adjusted EBITDA	(9,510,000)	(5,782,000)
Total assets	252,449,000
Investments in equity accounted investees	0
Goodwill	178,416,000
Purchase of property, plant and equipment, net	80,000
Operating Segments \| Rest of World
Net revenue
Net revenue	10,170,000	6,256,000
Share of loss from investments in equity accounted investees	1,643,000	1,172,000
Interest income	2,332,000	7,751,000
Interest expense	(6,000)	(7,000)
Interest income, net	2,326,000	7,744,000
Depreciation and amortization	664,000	654,000
Impairment loss on property, plant and equipment and right-of-use assets	0
Loss from discontinued operations	21,000
Adjusted EBITDA	(22,184,000)	(29,010,000)
Total assets	394,442,000
Investments in equity accounted investees	19,221,000
Goodwill	1,115,000
Purchase of property, plant and equipment, net	6,600,000
Corporate expenses
Net revenue
Net revenue	0	0
Share of loss from investments in equity accounted investees	0	0
Interest income	0	0
Interest expense	0	0
Interest income, net	0	0
Depreciation and amortization	0	0
Impairment loss on property, plant and equipment and right-of-use assets	0
Loss from discontinued operations	0
Adjusted EBITDA	(5,381,000)	(2,263,000)
Total assets	1,234,391,000
Investments in equity accounted investees	0
Goodwill	0
Purchase of property, plant and equipment, net	0
Cannabis flower
Net revenue
Net revenue	9,434,000	2,741,000
Cannabis flower \| Operating Segments \| United States
Net revenue
Net revenue	0	0
Cannabis flower \| Operating Segments \| Rest of World
Net revenue
Net revenue	9,434,000	2,741,000
Cannabis flower \| Corporate expenses
Net revenue
Net revenue	0	0
Cannabis extracts
Net revenue
Net revenue	3,144,000	5,576,000
Cannabis extracts \| Operating Segments \| United States
Net revenue
Net revenue	2,441,000	2,176,000
Cannabis extracts \| Operating Segments \| Rest of World
Net revenue
Net revenue	703,000	3,400,000
Cannabis extracts \| Corporate expenses
Net revenue
Net revenue	0	0
Other
Net revenue
Net revenue	33,000	115,000
Other \| Operating Segments \| United States
Net revenue
Net revenue	0	0
Other \| Operating Segments \| Rest of World
Net revenue
Net revenue	33,000	115,000
Other \| Corporate expenses
Net revenue
Net revenue	$ 0	$ 0

Segment Information - Schedule of Adjusted EBITDA (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Net income (loss)	$ (161,625,000)	$ 75,681,000
Interest income, net	(2,329,000)	(7,751,000)
Impairment loss on property, plant and equipment and right-of-use assets	1,741,000	0
Gain (loss) on revaluation of derivative liabilities	116,874,000	(113,368,000)
Other loss	1,859,000	378,000
Loss from discontinued operations	21,000	0
Share-based payments	2,499,000	2,436,000
Review costs related to restatement of 2019 interim financial statements	2,005,000	4,407,000
Adjusted EBIT	(38,955,000)	(38,217,000)
Depreciation and amortization	1,880,000	1,162,000
Adjusted EBITDA	(37,075,000)	(37,055,000)
Rest of World
Segment Reporting Information [Line Items]
Loss from discontinued operations	21,000	0
Operating Segments \| United States
Segment Reporting Information [Line Items]
Net income (loss)	(12,092,000)	(6,516,000)
Interest income, net	(3,000)	(7,000)
Impairment loss on property, plant and equipment and right-of-use assets	1,741,000
Gain (loss) on revaluation of derivative liabilities	0	0
Other loss	0	0
Loss from discontinued operations	0
Share-based payments	745,000	706,000
Review costs related to restatement of 2019 interim financial statements	0	0
Adjusted EBIT	(9,609,000)	(5,817,000)
Depreciation and amortization	99,000	35,000
Adjusted EBITDA	(9,510,000)	(5,782,000)
Operating Segments \| Rest of World
Segment Reporting Information [Line Items]
Net income (loss)	(142,147,000)	88,867,000
Interest income, net	(2,326,000)	(7,744,000)
Impairment loss on property, plant and equipment and right-of-use assets	0
Gain (loss) on revaluation of derivative liabilities	116,874,000	(113,368,000)
Other loss	1,859,000	378,000
Loss from discontinued operations	21,000
Share-based payments	1,754,000	1,730,000
Review costs related to restatement of 2019 interim financial statements	0	0
Adjusted EBIT	(23,965,000)	(30,137,000)
Depreciation and amortization	1,781,000	1,127,000
Adjusted EBITDA	(22,184,000)	(29,010,000)
Corporate expenses
Segment Reporting Information [Line Items]
Net income (loss)	(7,386,000)	(6,670,000)
Interest income, net	0	0
Impairment loss on property, plant and equipment and right-of-use assets	0
Gain (loss) on revaluation of derivative liabilities	0	0
Other loss	0	0
Loss from discontinued operations	0
Share-based payments	0	0
Review costs related to restatement of 2019 interim financial statements	2,005,000	4,407,000
Adjusted EBIT	(5,381,000)	(2,263,000)
Depreciation and amortization	0	0
Adjusted EBITDA	$ (5,381,000)	$ (2,263,000)

Segment Information - Schedule of Revenue from External Customers by Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 12,611	$ 8,432
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	7,582	6,091
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	2,441	2,176
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	2,518	0
Other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 70	$ 165

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Segment Information - Schedule of Long-lived Assets by Geographic Areas (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 192,123	$ 187,599
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	167,363	162,163
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	23,480	23,143
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1,280	$ 2,293

Commitments and Contingencies (Details) - Pending Litigation $ in Millions	Jun. 16, 2020 CAD ($)	Mar. 12, 2020 shareholder complaint
Litigation Relating to Marketing, Distribution and Sale of Products
Loss Contingencies [Line Items]
Damages sought	$ 500
Punitive damages sought	$ 5
U.S. District Court of Eastern District of New York Vs. Cronos
Loss Contingencies [Line Items]
Number of alleged shareholders \| shareholder		2
Number of putative class action complaints \| complaint		2

Financial Instruments - Schedule of Fair Value of Assets Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 1,024,450	$ 1,078,023
Short-term investments	214,925	211,766
Derivative liabilities	272,300	163,410
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,024,450	1,078,023
Short-term investments	214,925	211,766
Derivative liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Derivative liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Derivative liabilities	$ 272,300	$ 163,410

Financial Instruments - Credit Risk Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Concentration Risk [Line Items]
Maximum exposure to credit risk	$ 1,348,325	$ 1,403,491
Cash and cash equivalents	1,024,450	1,078,023
Short-term investments	$ 214,925	211,766
Accounts receivable, threshold period past due, writeoff	120 days
Current expected credit loss allowance on accounts receivable	$ 66	$ 74
Accounts Receivable \| Credit Concentration Risk \| Three Customers
Concentration Risk [Line Items]
Concentration risk, percentage	63.00%
Accounts Receivable \| Credit Concentration Risk \| Four Customers
Concentration Risk [Line Items]
Concentration risk, percentage		78.00%

Financial Instruments - Interest Rate Risk Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Interest income, net	$ 2,329	$ 7,751

Financial Instruments - Liquidity Risk Narrative (Details) - Accounts Payable - Supplier Concentration Risk	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Two Vendors
Concentration Risk [Line Items]
Concentration risk, percentage	26.00%
Four Vendors
Concentration Risk [Line Items]
Concentration risk, percentage		64.00%

Financial Instruments - Currency Rate Risk Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Foreign exchange gain (loss) on translation	$ 16,284	$ (113,692)
Impact of ten percent change in exchange rate	$ 156,828		$ 170,817

Held-For-Sale Assets and Discontinued Operations (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($) ft²	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Held-for-sale assets	$ 1,969		$ 1,176
Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Held-for-sale assets	$ 774		0
Disposal Group, Held-for-sale, Not Discontinued Operations \| OGBC \| Rest of World
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Area of building and land (in sqft) \| ft²	80,173
Discontinued Operations, Held-for-sale \| OGBC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations, net of income taxes	$ (21)	$ 0
Held-for-sale assets	$ 1,195		$ 1,176

- Definition

Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.

+ References + Details

Impairment Loss on Property, Plant and Equipment and Right-of-Use Assets (Details) ft² in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($) ft²
Leases [Abstract]
Impairment of leasehold improvements to be disposed of	$ 1,019
Lessee, operating lease, area of land to be disposed of (in sqft) \| ft²	6
Impairment charge on the de-recognition of the right-of-use asset	$ 702

Subsequent Events (Details) - Subsequent Event - NatuEra Series A Loan - Loans Receivable	Apr. 01, 2021 USD ($)
Subsequent Event [Line Items]
Advances to affiliates	$ 15,500,000
Transfer to investments in equity accounted investees	2,013,000
Cronos Group, Inc.
Subsequent Event [Line Items]
Advances to affiliates	$ 7,750,000
Funding commitment percentage	0.50
AGI
Subsequent Event [Line Items]
Advances to affiliates	$ 7,750,000
Funding commitment percentage	0.50